KEYNOTE-010

NCT01905657 📎

Regimen

Experimental
pembrolizumab 2 or 10 mg/kg
Control
docetaxel

Population

Pretreated PD-L1≥1% advanced NSCLC

Key finding

mOS pembro 2mg vs doc 10.4 vs 8.5 mo, HR 0.71 (0.58-0.88); PD-L1≥50% HR 0.54

Source: PMID 26712084

Timeline

  • Enrollment start: 2013-08-09 📎

Guideline citations

  • NCCN NSCLC Version 5.2026 (p.183)
  • CSCO NSCLC 2025 ⚠️ OCR source